Abstract
Multidrug resistance has became the major obstacle to cancer chemotherapy. Recent studies suggest that quercetin could enhance the response of tumors to chemotherapy although the mechanism by which quercetin enhances the sensitivity of tumor cells to chemical drugs remains elusive. Therefore, in this study, we examined the effects of quercetin on doxorubicin cytotoxicity in human breast cancer cells and investigated the underlying mechanisms. MCF-7 and MCF-7/ dox cells were exposed to doxorubicin, quercetin, or combination of both agents for 36 hours. Cell proliferation, cell invasion, intracellular doxorubicin concentration and expression of hypoxia-inducible factor-1 alpha (HIF-1α) and P-glycoprotein (P-gp) were then assessed. Quercetin had little effect on cell proliferation at concentrations less than 0.7 μM. Compared to treatment with doxorubicin alone, combined treatment with doxorubicin and quercetin (0.7 μM) significantly inhibited cell proliferation and invasion and suppressed the expression of HIF-1α and P-gp. Quercetin (0.7 μM) increased the intracellular doxorubicin concentration and enhanced doxorubicin cytotoxicity as 1.49-fold in MCF-7 cells and 1.98-fold in MCF-7/dox cells. These data suggest that quercetin can increase the chemosensitivity of breast cancer cells to doxorubicin.
Keywords: Doxorubicin, Quercetin, Chemotherapy, Cytotoxicity
Anti-Cancer Agents in Medicinal Chemistry
Title:The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells
Volume: 13 Issue: 2
Author(s): Shi-zheng Li, Kun Li, Jun-hua Zhang and Zhe Dong
Affiliation:
Keywords: Doxorubicin, Quercetin, Chemotherapy, Cytotoxicity
Abstract: Multidrug resistance has became the major obstacle to cancer chemotherapy. Recent studies suggest that quercetin could enhance the response of tumors to chemotherapy although the mechanism by which quercetin enhances the sensitivity of tumor cells to chemical drugs remains elusive. Therefore, in this study, we examined the effects of quercetin on doxorubicin cytotoxicity in human breast cancer cells and investigated the underlying mechanisms. MCF-7 and MCF-7/ dox cells were exposed to doxorubicin, quercetin, or combination of both agents for 36 hours. Cell proliferation, cell invasion, intracellular doxorubicin concentration and expression of hypoxia-inducible factor-1 alpha (HIF-1α) and P-glycoprotein (P-gp) were then assessed. Quercetin had little effect on cell proliferation at concentrations less than 0.7 μM. Compared to treatment with doxorubicin alone, combined treatment with doxorubicin and quercetin (0.7 μM) significantly inhibited cell proliferation and invasion and suppressed the expression of HIF-1α and P-gp. Quercetin (0.7 μM) increased the intracellular doxorubicin concentration and enhanced doxorubicin cytotoxicity as 1.49-fold in MCF-7 cells and 1.98-fold in MCF-7/dox cells. These data suggest that quercetin can increase the chemosensitivity of breast cancer cells to doxorubicin.
Export Options
About this article
Cite this article as:
Li Shi-zheng, Li Kun, Zhang Jun-hua and Dong Zhe, The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (2) . https://dx.doi.org/10.2174/1871520611313020020
DOI https://dx.doi.org/10.2174/1871520611313020020 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Activity of 3-N-Substituted Estrogen Derivatives as Breast Cancer Agents
Mini-Reviews in Medicinal Chemistry Bisphosphonates in the Prevention of Disease Recurrence: Current Results and Ongoing Trials
Current Cancer Drug Targets Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Boron Nitride Nanotubes: Production, Properties, Biological Interactions and Potential Applications as Therapeutic Agents in Brain Diseases
Current Nanoscience Heavy Metals and Epigenetic Alterations in Brain Tumors
Current Genomics Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets
Current Signal Transduction Therapy Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone
Current Pharmaceutical Biotechnology Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Similar and Shared Nongenomic Mechanisms of Action of Estrogen and Thyroid Hormone
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters Membrane Transporters in Physiological Barriers of Pharmacological Importance
Current Pharmaceutical Design Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Docking Investigation on Bis (Nitro Indazolyl) Methanes; Synthesis and Antimicrobial Activity Towards Breast Cancer Applications
Letters in Organic Chemistry Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design